tadalafil has been researched along with zaprinast in 9 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (zaprinast) | Trials (zaprinast) | Recent Studies (post-2010) (zaprinast) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 576 | 2 | 87 |
| Protein | Taxonomy | tadalafil (IC50) | zaprinast (IC50) |
|---|---|---|---|
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 1.9442 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Canis lupus familiaris (dog) | 0.76 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Bos taurus (cattle) | 2.6 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | 3.55 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Bos taurus (cattle) | 2.6 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Homo sapiens (human) | 3.55 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | 3.55 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Bos taurus (cattle) | 0.4 | |
| G-protein coupled receptor 35 | Homo sapiens (human) | 0.8294 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Hughes, RA; Manallack, DT; Thompson, PE | 1 |
| Antunes, JE; da Cunha, EF; Freitas, MP; Ramalho, TC; Rittner, R | 1 |
| Beghyn, TB; Bourin, A; Charton, J; Cos, P; Deprez, B; Laconde, G; Leroux, F; Maes, L | 1 |
| Leeson, PD; Young, RJ | 1 |
| Chai, S; Chen, S; Deng, L; Du, K; Shen, R; Sun, H; Sun, T; Xi, M; Xie, M | 1 |
| Bowles, EA; Ellsworth, ML; Elrick, MM; Knebel, SM; Sprague, RS; Stephenson, AH; Zdanovec, AK | 1 |
| Bowles, EA; Ellsworth, ML; Moody, GN; Sprague, RS; Stephenson, AH; Yeragunta, Y | 1 |
| Aronsen, L; Lysaa, R; Orvoll, E; Ravna, AW; Sager, G | 1 |
| Ding, S; Huang, X; Liu, L; Song, G; Wang, D; Xu, H | 1 |
4 review(s) available for tadalafil and zaprinast
| Article | Year |
|---|---|
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines | 2005 |
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
Topics: Animals; Chemical Phenomena; Drug Discovery; Humans; Hydrophobic and Hydrophilic Interactions | 2018 |
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alzheimer Disease; Animals; Cognition; Cyclic GMP; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 2022 |
Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognition; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Flavonoids; Humans; Neurons; Neuroprotective Agents; Phosphodiesterase 5 Inhibitors; Purinones; Pyrimidines; Signal Transduction; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride | 2019 |
5 other study(ies) available for tadalafil and zaprinast
| Article | Year |
|---|---|
In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.
Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Imidazoles; Mice; Models, Molecular; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Quantitative Structure-Activity Relationship; Rats; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2008 |
Drug to genome to drug: discovery of new antiplasmodial compounds.
Topics: Amino Acid Sequence; Antimalarials; Carbolines; Catalytic Domain; Cyclic AMP; Cyclic GMP; Diketopiperazines; Drug Design; Drug Discovery; Genome, Human; Genome, Protozoan; Humans; Hydrolysis; Models, Molecular; Molecular Sequence Data; Parasitic Sensitivity Tests; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Plasmodium falciparum; Stereoisomerism; Structure-Activity Relationship; Tadalafil | 2011 |
Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3',5' monophosphate accumulation and adenosine 3'5' triphosphate release from human erythrocytes.
Topics: Adenosine Triphosphate; Adult; Carbolines; Cyclic AMP; Epoprostenol; Erythrocytes; Female; Humans; Iloprost; Male; Middle Aged; Phosphodiesterase Inhibitors; Purinones; Signal Transduction; Tadalafil; Vasodilator Agents | 2013 |
Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Antihypertensive Agents; Carbolines; Cyclic AMP; Drug Synergism; Epoprostenol; Erythrocytes; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Purinones; Tadalafil; Young Adult | 2015 |
Modulation of high affinity ATP-dependent cyclic nucleotide transporters by specific and non-specific cyclic nucleotide phosphodiesterase inhibitors.
Topics: ATP-Binding Cassette Transporters; Caffeine; Carbolines; Cyclic AMP; Cyclic GMP; Dipyridamole; Humans; Imidazoles; Kinetics; Multidrug Resistance-Associated Proteins; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purinones; Sulfones; Tadalafil; Theophylline; Triazines; Vardenafil Dihydrochloride | 2014 |